Cabaletta Bio (CABA) offers a de-risked, breadth-first CAR-T platform for autoimmune diseases, with

Cabaletta Bio, Inc. (CABA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 T

83% of dermatomyositis patients in the Phase 1/2 RESET-Myositis study would have met the registratio

83% of dermatomyositis patients in the Phase 1/2 RESET-Myositis study would have met the registratio

Here is how Cabaletta Bio, Inc. (CABA) and Curaleaf Holdings, Inc. (CURLF) have performed compared t

Cabaletta Bio (CABA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about t

Wells Fargo analyst Derek Archila maintains Cabaletta Bio (NASDAQ:CABA) with a Equal-Weight and r

Cabaletta Bio, Inc. is reaffirmed as a Buy despite recent share price volatility, driven by tangible

Cabaletta Bio (NASDAQ:CABA) reported quarterly losses of $(0.39) per share which met the analyst con

Preconditioning-free (PC-free) 6-to-9-month clinical data with a single infusion of the lowest dose

A single infusion of the lowest dose of rese-cel administered without preconditioning, after discont

Global Business Travel Group Inc (GBTG), a NYSE-listed company, saw its stock rise 57% on Monday af

Cantor Fitzgerald analyst Josh Schimmer reiterates Cabaletta Bio (NASDAQ:CABA) with a Overweight

Cabaletta Bio, Inc. ("Cabaletta" or the "Company") (NASDAQ:CABA), a clinical-stage b

PHILADELPHIA, May 04, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (N

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cellares, the first Integrated Development and Manufac

Agreement facilitates flexible, scalable automated industrialized production of rese-cel for many th

PHILADELPHIA, April 27, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage cl

First two GMP doses of rese-cel manufactured on the Cell Shuttle™ met all release specifications, we

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cellares, the first Integrated Development and Manufac

Dow futures down 0.1%. FGI Industries (NASDAQ: FGI) reported mixed results for Q4, with losses of 29

Analysts change ratings & price targets for HSCS, ONDS, STRO, PFE, HST, CABA, INSM, PVH. See ful

Morgan Stanley analyst Michael Ulz maintains Cabaletta Bio (NASDAQ:CABA) with a Overweight and lo

Guggenheim analyst Yatin Suneja maintains Cabaletta Bio (NASDAQ:CABA) with a Buy and raises the p

Cabaletta Bio (NASDAQ:CABA) reported quarterly losses of $(0.40) per share which beat the analyst co

Rese-cel myositis BLA submission on track for 2027 based on a 17-patient, single arm registrational

Cabaletta Bio (NASDAQ: CABA) used a fireside chat at TD Cowen's 46th Annual Health Care Conference t

Cabaletta Bio (CABA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about t

PHILADELPHIA, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage cli

PHILADELPHIA, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage cli

Does Cabaletta Bio, Inc. (CABA) have what it takes to be a top stock pick for momentum investors? Le

  On Thursday, 1076 companies hit new 52-week lows.

  Wednesday's session saw 269 companies set new 52-week lows.

  During Monday's trading, 1214 companies set new 52-week lows.

    Tuesday's session saw 729 companies set new 52-week lows.

Stocks That Hit 52-Week Lows On Monday